Regenerative effects of peptide nanofibers in an experimental model of Parkinson's disease

被引:15
|
作者
Sever, Melike [1 ]
Turkyilmaz, Mesut [2 ]
Sevinc, Cansu [2 ]
Cakir, Aysen [3 ]
Ocalan, Busra [3 ]
Cansev, Mehmet [2 ]
Guler, Mustafa O. [1 ]
Tekinay, Ayse B. [1 ]
机构
[1] Bilkent Univ, Natl Nanotechnol Res Ctr UNAM, Inst Mat Sci & Nanotechnol, TR-06800 Ankara, Turkey
[2] Uludag Univ, Dept Pharmacol, Sch Med, TR-16059 Bursa, Turkey
[3] Uludag Univ, Dept Physiol, Sch Med, TR-16059 Bursa, Turkey
关键词
Parkinson's disease; 6-Hydroxydopamine; Peptide amphiphiles; Laminin mimetic; Heparan sulfate mimetic; HEPARAN-SULFATE; GROWTH-FACTOR; RAT MODEL; MICROGLIA; APOPTOSIS; MODULATION; PATHWAYS; AKINESIA; NEURONS; 6-OHDA;
D O I
10.1016/j.actbio.2016.09.011
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Parkinson's disease (PD) is characterized by progressive degeneration of dopaminergic nigrostriatal neurons and reduction in striatal dopamine levels. Although there are few treatment options for PD such as Levodopa, they are used just to relieve and modify the symptoms. There are no therapies available for PD to slow down the degeneration process in the brain and recover the lost function. In this study, we used extracellular matrix (ECM) mimetic peptide amphiphile (PA) nanofibers as a potential therapeutic approach in a PD rat model. We demonstrated the effect of heparan sulfate mimetic and laminin mimetic PA nanofibers on reducing striatal injury and enhancing functional recovery after unilateral striatal injection of 6-hydroxydopamine (6-OHDA). The bioactive self-assembled PA nanofibers significantly reduced forelimb asymmetry, contralateral forelimb akinesia and d-amphetamine-induced rotational behavior in cylinder, stepping and rotation tests, respectively, in 6-OHDA-lesioned rats after 6 weeks. The behavioral improvement with PA nanofiber administration was associated with enhanced striatal dopamine and tyrosine hydroxylase content as well as reduced cleaved-Caspase-3 levels. Histological assessment also showed that PA nanofiber injection to the striatum resulted in better tissue integrity compared to control groups. In addition, PA nanofibers reduced the progressive cell loss in SH-SYSY cells caused by 6-OHDA treatment. These data showed that the bioactive peptide nanofibers improve neurochemical and behavioral consequences of Parkinsonism in rats and provide a promising new strategy for treatment of PD. Statement of Significance Biomimetic nanomaterials bearing natural bioactive signals which are derived from extracellular matrix components like laminin and heparan sulfates provide promising therapeutic strategies for regeneration of the nervous system. However, no research has been reported exploring the use of biomimetic materials against degeneration in Parkinson's disease. In this work, we investigated potential therapeutic effects of heparan sulfate and laminin mimetic PA nanofibers on reduction of striatal injury in experimental Parkinson's disease model. PA nanofibers enhanced functional recovery associated with enhanced striatal dopamine and tyrosine hydroxylase content as well as reduced cleaved-Caspase-3 levels. Overall, this study shows the improvement in consequences of Parkinsonism in rats and provides a new platform for treatment of Parkinson's disease. (C) 2016 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:79 / 90
页数:12
相关论文
共 50 条
  • [21] Mechanism of the beneficial effect of melatonin in experimental Parkinson's disease
    Yildirim, Fatos Belgin
    Ozsoy, Ozlem
    Tanriover, Gamze
    Kaya, Yasemin
    Ogut, Eren
    Gemici, Burcu
    Dilmac, Sayra
    Ozkan, Ayse
    Agar, Aysel
    Aslan, Mutay
    NEUROCHEMISTRY INTERNATIONAL, 2014, 79 : 1 - 11
  • [22] The effect of chronic neuropeptide-S treatment on non-motor parameters in experimental model of Parkinson's disease
    Sinen, Osman
    Bulbul, Mehmet
    Derin, Narin
    Ozkan, Ayse
    Akcay, Guven
    Aslan, Mutay Aydin
    Agar, Aysel
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2021, 131 (08) : 765 - 774
  • [23] Neuroprotective Effects of the Small-Molecule Enhancer of Rapamycin in the Cellular Model of Parkinson’s Disease
    S. Darabi
    A. Noori-Zadeh
    F. Rajaei
    H. A. Abbaszadeh
    M.-A. Abdollahifar
    S. Bakhtiyari
    Neurophysiology, 2019, 51 : 88 - 96
  • [24] Neurorestorative effects of sub-chronic administration of ambroxol in rodent model of Parkinson's disease
    Mishra, Akanksha
    Krishnamurthy, Sairam
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2020, 393 (03) : 429 - 444
  • [25] Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson's Disease
    Requejo, C.
    Ruiz-Ortega, J. A.
    Bengoetxea, H.
    Bulnes, S.
    Ugedo, L.
    Lafuente, J. V.
    MOLECULAR NEUROBIOLOGY, 2018, 55 (01) : 201 - 212
  • [26] Neuroprotective Effects of Antidepressants via Upregulation of Neurotrophic Factors in the MPTP Model of Parkinson's Disease
    Shadfar, Sina
    Kim, Yu-Gyeong
    Katila, Nikita
    Neupane, Sabita
    Ojha, Uttam
    Bhurtel, Sunil
    Srivastav, Sunil
    Jeong, Gil-Saeng
    Park, Pil-Hoon
    Hong, Jin Tae
    Choi, Dong-Young
    MOLECULAR NEUROBIOLOGY, 2018, 55 (01) : 554 - 566
  • [27] Neuroprotective effects of echinacoside in the mouse MPTP model of Parkinson's disease
    Geng, Xingchao
    Tian, Xuefei
    Tu, Pengfei
    Pu, Xiaoping
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2007, 564 (1-3) : 66 - 74
  • [28] Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease
    Chen, YiMei
    Zhang, Yanfang
    Li, Lin
    Hoelscher, Christian
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2015, 768 : 21 - 27
  • [29] BDNF RECEPTOR BLOCKADE HINDERS THE BENEFICIAL EFFECTS OF EXERCISE IN A RAT MODEL OF PARKINSON'S DISEASE
    Real, C. C.
    Ferreira, A. F. B.
    Chaves-Kirsten, G. P.
    Torrao, A. S.
    Pires, R. S.
    Britto, L. R. G.
    NEUROSCIENCE, 2013, 237 : 118 - 129
  • [30] Neuroprotective Effects of the Small-Molecule Enhancer of Rapamycin in the Cellular Model of Parkinson's Disease
    Darabi, S.
    Noori-Zadeh, A.
    Rajaei, F.
    Abbaszadeh, H. A.
    Abdollahifar, M-A
    Bakhtiyari, S.
    NEUROPHYSIOLOGY, 2019, 51 (02) : 88 - 96